Antibody–Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors
Zhaoling Jiang, Chen Mei, Xueze Lyu, Zhenyi Liu, Zhihua Li, Baozhu Xing, Ying Liu, Gebin Li, Hongjun Wang · 2026
Read Antibody–Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors by Zhaoling Jiang, Chen Mei, Xueze Lyu, Zhenyi Liu, Zhihua Li, Baozhu Xing, Ying Liu, Gebin Li, Hongjun Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13516091.txt.
Description
Zhaoling Jiang and eight colleagues review antibody-drug conjugates aimed at two tumour targets, HER2 and Trop-2, in a 2026 article. Both proteins sit in excess on many solid tumours and drive growth, spread, and drug resistance. A conjugate couples a homing antibody to a potent cell-killing payload, so the poison lands mainly inside cancer cells. The review lays out how each target works and promotes cancer.
Clinical results then take centre stage across breast, stomach, lung, and bladder cancers. Named drugs such as trastuzumab deruxtecan and sacituzumab govitecan show strong, lasting responses, even in tumours with low HER2 levels and after earlier lines of treatment failed. The authors weigh response data and prospects, then close with the field's open problems, from resistance to side effects. Their verdict: these conjugates are now a real force in precision cancer care, with room to grow.
Catalog record
| CREATOR | Zhaoling Jiang, Chen Mei, Xueze Lyu, Zhenyi Liu, Zhihua Li, Baozhu Xing, Ying Liu, Gebin Li, Hongjun Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |